A RIPK1-specific PROTAC degrader achieves potent antitumour activity by enhancing immunogenic cell death. Mannion et al.
Published: 24 May 2024| Version 1 | DOI: 10.17632/822syk52yw.1
Contributors:
, , , , Laura Ramos Garcia, Rebecca Wilson, Sidonie Wicky John, Savita Udainiya, Emmanuel Patin, Crescens Tiu, Angel Smith, , Andrew Craxton, Nathalia Moraes de Vasconcelos, Naomi Guppy, Kwai-Ming J Cheung, Nicholas J. Cundy, Olivier Pierrat, Alfie Brennan, Theodoros I. Roumeliotis, Graeme Bensead-Hume, John Alexander, Gareth Muirhead, Scott Layzell, Wenxin Lyu, Victoria Roulstone, Mark Allen, Holly Balldock, Arnaud Legrand, Florian Gabel, Natalia Serrano-Aparicio, Chris Starling, Hongyan Guo, Jason Upton, Mads Gyrd-Hansen, Marion MacFarlane, Benedict Seddon, Florence Raynaud, Ioannis Roxanis, Kevin Harrington, , Jyoti S. Choudhary, Swen Hoelder, , Description
Original data from the images and western blots from the paper: A RIPK1-specific PROTAC degrader achieves potent antitumour activity by enhancing immunogenic cell death.
Files
Institutions
- Institute of Cancer Research
Categories
Molecular Biology, Radiation, Cancer, Innate Immunity, Immune Checkpoint Inhibitor, Immunogenic Cell Death
Funders
- Breast Cancer NowUnited Kingdom
- Cancer Research UKUnited Kingdom